SOURCE: Peregrine Pharmaceuticals

Peregrine Pharmaceuticals

February 27, 2012 16:00 ET

Peregrine Announces Participation at Upcoming Investor Conferences in March

TUSTIN, CA--(Marketwire - Feb 27, 2012) - Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM), a clinical-stage biopharmaceutical company developing first-in-class monoclonal antibodies for the treatment of cancer and infectious diseases, today announced that Steven King, president and CEO, will present at the following two investor conferences in March:

  • 32nd Cowen Health Care Conference on Monday, March 5, 2012, at 4:10pm Eastern Time at the Marriott Copley Hotel in Boston
  • 24th Annual ROTH Conference on Monday, March 12, 2012, at 11:00am Pacific Time at the Ritz Carlton Hotel in Laguna Nigel

Peregrine's presentation at the 24th Annual Roth Conference will be webcast live and available for replay until April 2, 2012 at:

About Peregrine Pharmaceuticals
Peregrine Pharmaceuticals, Inc. is a biopharmaceutical company with a portfolio of innovative monoclonal antibodies in clinical trials for the treatment of cancer and serious viral infections. The company is pursuing multiple clinical programs in cancer and infectious disease with its lead product candidate bavituximab and novel brain cancer agent Cotara®. Peregrine also has in-house cGMP manufacturing capabilities through its wholly-owned subsidiary Avid Bioservices, Inc. (, which provides development and biomanufacturing services for both Peregrine and outside customers. Additional information about Peregrine can be found at

Contact Information

  • Contact:
    Christopher Keenan or Jay Carlson
    Peregrine Pharmaceuticals
    (800) 987-8256